BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23603367)

  • 21. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
    Ewies AA; Alfhaily F
    Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system.
    Engemise SL; Willets JM; Taylor AH; Emembolu JO; Konje JC
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):101-6. PubMed ID: 21470761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
    Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
    Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study.
    Derbyshire AE; Allen JL; Gittins M; Lakhiani B; Bolton J; Shaw J; Pemberton PW; Needham M; MacKintosh ML; Edmondson RJ; Kitchener HC; Crosbie EJ
    Cancer Prev Res (Phila); 2021 Feb; 14(2):263-274. PubMed ID: 32998940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL; Holland C
    Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of levonorgestrel intrauterine system on endometrial tissue after endometrial polyps resection by hysteroscopy].
    Cai HL; Ding XC; Qian RR; Yu RF; Sun LM; Li Q
    Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(3):200-2. PubMed ID: 22490745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
    Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
    Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
    Varma R; Sinha D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
    Qi X; Zhao W; Duan Y; Li Y
    Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
    Gallos ID; Ganesan R; Gupta JK
    Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
    Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM
    Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.